NextCure, Inc. — Form 8-K
Filed November 10, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
NextCure is advancing its proposed merger with Avere Therapeutics, which is now supported by approximately $820 million in committed financing ($320M concurrent private placement + $500M additional private placement, with ~$266M satisfied via contribution/cancellation of Avere convertible notes). The SEC declared the S-4 registration statement effective on November 6, 2026, with stockholders scheduled to vote on December 9, 2026. NextCure simultaneously completed major restructuring—workforce reductions, facility lease terminations, asset sales—and transitioned the LNCB74 program to LigaChem while retaining milestone and royalty rights.
Why this rating
Merger is existential for $12.6M company. $820M financing substantially exceeds NextCure's size (65x market value), enabling transformational combination and provides path for shareholder value via CVRs on legacy assets. Vote imminent; regulatory approval secured.
Tradability signal
NO TRADE
No trade: positive news with only +3.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -1.05% over 4 hrs, n=25). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $5.78 ▼ 3.34% | at our read · unknown $5.98 | +10 min · unknown $5.98 ▲ 0.00% | +30 min · unknown $5.98 ▲ 0.00% | +1 hr · unknown $5.55 ▼ 7.22% | +4 hrs · unknown $5.42 ▼ 9.28% |
The stock had already moved +3.46% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 10, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.